AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 282 min read$CYTK

Blum Robert I sold $579K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $77.21 ($0.58M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and post-transaction holdings, which can influence short-term sentiment but does not introduce new operating or financial information.

02

Market read

This is a routine insider-sale disclosure with modest sentiment relevance, not a fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, trials, or financing, the filing is unlikely to alter valuation fundamentals.

Relevance 4/10Novelty 3/10Timing: filed 2026-05-28, sale dated 2026-05-27

Background

The article is a SEC Form 4 insider transaction disclosure for Cytokinetics, Inc. (CYTK) by its President and CEO.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOKINETICS CEO Robert Blum filed a Form 4 selling 7,500 shares at $77.21 on 2026-05-27 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than a new fundamental catalyst.

Evidence & confidence

The filing is primary-source and time-stamped, but it is explicitly pre-arranged under Rule 10b5-1, which typically dampens interpretive value for traders.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity planning rather than bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • insider
    Blum Robert I

    President and CEO who sold 7,500 shares at $77.21 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

SEP 12
$CYTKMedAI 8/10

Cytokinetics (CYTK) Shares In Focus After New Phase 3 Aficamten Data

Cytokinetics (CYTK) reported detailed Phase 3 trial results for aficamten, showing efficacy and safety in hypertrophic cardiomyopathy. The company plans to file a supplemental drug application, aiming to expand its cardiology franchise. Cytokinetics has a market cap of $10.3 billion and focuses on muscle-related diseases. Regulatory uncertainty and a small pipeline remain risks.

simplywall.st2 min
SEP 11
$CYTKMed

Cantor Fitzgerald reiterates Overweight on Cytokinetics stock

Cantor Fitzgerald reiterated an Overweight rating on Cytokinetics (CYTK), citing strong commercial and regulatory outlooks. The stock has risen 38% over the past year, trading at $73.62 with a $10.23B market cap. Analysts have raised earnings estimates, though profitability is not expected this year. Management expects 50% new prescription share by year-end and potential REMS relaxation. Cytokinetics reported Q2 sales of $25.3M for Myqorzo, exceeding estimates. Barclays and Citizens raised price

investing.com2 min
SEP 8
$CYTKMedAI 8/10

Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

finance.yahoo.com2 min
SEP 2
$CYTKMedAI 8/10

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics (CYTK) presented additional results from ACACIA-HCM and MAPLE-HCM studies at the European Society of Cardiology Congress 2026, showing aficamten's benefits in non-obstructive HCM (nHCM) and superiority over metoprolol in obstructive HCM (oHCM). CYTK plans to submit an sNDA for aficamten in nHCM in Q4 2026. Myqorzo (aficamten) faces competition from Bristol Myers Squibb's (BMY) Camzyos and Edgewise Therapeutics' (EWTX) EDG-7500. CYTK shares are up 12.4% YTD, trading at 26.6X forward

finance.yahoo.com3 min
AUG 31
$CYTKMedAI 9/10

What's Going On With Cytokinetics Stock Today? - Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) reported positive results from its ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy, meeting primary endpoints and showing improvements in symptoms and exercise performance. The drug showed benefits in five key areas, but some safety concerns were noted. Cytokinetics plans to file for FDA approval in Q4 2026. Shares fell 3.19% to $69.79.

benzinga.com2 min